Calliditas Therapeutics AB (publ)
CLTEF · OTC
5/31/2025 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 55,710.46 | -0.75 | 5.03 | -53.85 |
| FCF Yield | -0.20% | -10.96% | -0.72% | -0.93% |
| EV / EBITDA | -327.62 | -10.58 | -10.03 | -11.13 |
| Quality | ||||
| ROIC | -7.80% | -25.98% | -259.09% | -335.59% |
| Gross Margin | -55.77% | 94.99% | 9.40% | 100.00% |
| Cash Conversion Ratio | 1.13 | 0.93 | 0.76 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | -97.17% | 73.94% | 872.10% | 126.50% |
| Free Cash Flow Growth | -145.66% | -1,387.39% | 41.88% | -37.71% |
| Safety | ||||
| Net Debt / EBITDA | -0.00 | -0.01 | 0.06 | 0.10 |
| Interest Coverage | -274.31 | -8.46 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 2.96 | 4.17 | 0.00 |
| Cash Conversion Cycle | -882.44 | -429.05 | -40,094.36 | 0.00 |